Why the study?
Does intravenous rt-PA improve clinical outcomes in a patient with ischemic stroke and presumed ventricular myxoma?
Does intravenous rt-PA improve clinical outcomes in a patient with ischemic stroke and presumed ventricular myxoma?
Intravenous rt-PA was successfully used to treat an ischemic stroke in a patient with a presumed ventricular myxoma without complications.
IV rt-PA may be feasible in stroke with presumed ventricular myxoma; hypothesis-generating case report requiring prospective confirmation.
Background. Although thrombolytic therapy has been shown to be beneficial to stroke patients, the effectiveness of intravenous thrombolysis in ischemic stroke patients with ventricle myxoma is unknown. Case Description. A 22-year-old woman with left hemiplegia was sent to the emergency department at a teaching hospital. The magnetic resonance angiography showed occlusion of the right middle cerebral artery, and the echocardiography showed a mass in the left ventricle. Intravenous recombined tissue plasminogen activator (rt-PA) was administrated, and the postthrombolysis transcranial Doppler exam showed that her right middle cerebral artery was circulative. The patient's condition improved gradually, and no complication was observed up to 16 months of follow-up. Conclusion. Intravenous rt-PA is a reasonable treatment for stroke patients with ventricle myxoma.
No takes yet. Share an insight, caveat, or question.
Ong et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: